You are here: Industry Insights > Market News > Zydus Cadila gets tentative US FDA approval for Brivaracetam tablets

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

Hot Products

Propantheline Bromide

carbomer 974P

Coenzyme Q10

Refined Fish Oil

Black Currant Extract

Hydrocortisone

Zydus Cadila gets tentative US FDA approval for Brivaracetam tablets

expresspharmaJune 16, 2021

Tag: Zydus , FDA , Brivaracetam , epilepsy

Favorites

Zydus Cadila has received tentative approval from the USFDA to market Brivaracetam Tablets, in the strengths of 10 mg, 25 mg, 50 mg, 75 mg, and 100 mg (US RLD: Briviact Tablets). Brivaracetam is used to treat partial-onset of seizures (epilepsy).

Zydus Cadila gets tentative US FDA approval for Brivaracetam tablets

The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad. The group now has 319 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.

Previous:Mikart Expands Oral Solids Production Capabilities

Next:An Emerging Target for Solid Tumors -- CD73 Development in China

InnoCare Sets up Specific Environment Management Target in its Fifth ESG Report

PharmaSourcesApril 28, 2024

InnoCare Pharma, a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases.

Touchlight Awarded Grant Extension to Further Develop DNA-Enabled Biobatteries with U.S. Office for Naval Research and UK Defence Science & Technology Laboratory

Biotech NewswireApril 26, 2024

Study Results of Orelabrutinib in Patients with ITP Published by the American Journal of Hematology

PharmaSourcesApril 18, 2024

Zydus Cadila gets tentative US FDA approval for Brivaracetam tablets | Pharmasources.com

Autonomix Medical Inc. Covered in Benzinga Article Highlighting Innovative Nerve Treatment Technology

PharmaSourcesApril 17, 2024

Company is targeting pancreatic cancer pain with advanced nerve detection and treatment technology

Zydus Cadila gets tentative US FDA approval for Brivaracetam tablets

Related News

InnoCare Sets up Specific Environment Management Target in its Fifth ESG Report

Touchlight Awarded Grant Extension to Further Develop DNA-Enabled Biobatteries with U.S. Office for Naval Research and UK Defence Science & Technology Laboratory

Study Results of Orelabrutinib in Patients with ITP Published by the American Journal of Hematology

Autonomix Medical Inc. Covered in Benzinga Article Highlighting Innovative Nerve Treatment Technology

You may like